SMS Pharmaceuticals Limited (SMS Pharma) shares that its  Unit VII manufacturing facility in Visakhapatnam, Andhra Pradesh, has received prequalification approval from the World Health Organisation (WHO) Geneva.

This significant milestone enhances our global regulatory standing and enables the company to increase its presence in the global market for Anti-Retroviral (ARV) APIs.

Commenting on this achievement, P. Vamsi Krishna, Executive Director, stated: "The WHO Geneva prequalification reflects the company's strong compliance with stringent international regulatory standards, reinforcing its reputation for quality, reliability, and global competitiveness."